Defective interleukin-1 receptor antagonist production is associated with resistance of acute liver graft rejection to steroid therapy

American Journal of Pathology

Volumn 157, Issue 5, 2000, Pages 1685-1692

  Conti, Filomena ^a   Breton, Sylvie ^a   Batteux, Frédéric ^a   Furlan, Valérie ^b   Houssin, Didier ^c   Weill, Bernard ^a   Calmus, Yvon ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICÊTRE HOSPITAL   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; STEROID;

ADULT; AGED; ARTICLE; CYTOKINE PRODUCTION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0033678696     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64805-5     Document Type: Article

References (56)

1. Patterns of graft rejection following liver transplantation
2. Rejection in liver transplantation
3. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection
4. Treatment of acute rejection
5. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
6. OKT3 treatment for aliograft rejection is a risk factor for cytomegaiovirus disease in liver transplantation
7. OKT3-induced hypotension in heart allograft recipients treated for steroid-resistant rejection
8. Chronic rejection after liver transplantation: A study of clinical, histopathological and immunological features
9. Biologic basis for interleukin-1 in disease
10. Endothelial activation and cytokine expression in human acute cardiac allograft rejection
11. Alterations in renal interleukin-1 production during kidney transplant rejection in the rat. The effects of high-dose methylprednisolone
12. Production of cytokines (TNF-alpha, IL-1-beta) and endothelial cell activation in human liver allograft rejection
13. Anti-inflammatory actions of steroids: Molecular mechanisms
14. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Post-transcriptional mechanisms
15. The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes
16. The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interfeukin-1 beta, receptor antagonist and interleukin-10 in human volunteers
17. Primary structure and functional expression from complementary DNA of human interleukin-1 receptor antagonist
18. An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties
19. Purification, cloning, expression, and biological characterization of an interleukin-1 receptor antagonist protein
20. Interleukin-1 receptor antagonist activity of an interleukin-1 inhibitor
21. Interleukin-1 and interleukin-1 antagonism
22. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor
23. A urine inhibitor of interleukin-1 activity that blocks ligand binding
24. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction
25. Interleukin-1 receptor antagonist blocks chemokine production in the mixed lymphocyte reaction
26. Interleukin-1 receptor antagonist: Role in biology
27. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis
28. Blocking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro
29. Monocytes-macrophages and cytokines/chemokines in fine-needle aspiration biopsy cultures. Enhanced interleukin-1 receptor antagonist in rejection-free kidney transplant patients
30. Immunoenzymatic labelling of monoclonal antibodies using immune complex of alkaline phosphatase and monoclonal anti-alkaline phosphatase
31. Bone marrow histologic and immunohistochemical findings in peripheral T-cell lymphoma: A study of 38 cases
32. Human monocyte/macrophage activation and interleukin 1 generation by biomedical polymers
33. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat
34. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes
35. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta)
36. A Taql polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro
37. IL-1 receptor antagonist (IL-1Ra) is an acute-phase protein
38. Inhibition of the production and effects of interleukin 1 and tumor necrosis factor alpha in rheumatoid arthritis
39. Presence of the IL-1Ra allele 2 (IL1RN*2) is associated with enhanced IL-1 beta production in vitro
40. Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus
41. Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2
42. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases
43. Genetic markers may predict disease behavior in patients with ulcerative colitis
44. Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma
45. Corticosteroid pharmacokinetics in asthma
46. Glucocorticoid resistance in chronic asthma: Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids
47. Steroid-resistant asthma: Immunologic and pharmacologic features
48. Methylprednisolonehemisuccinate and its metabolites in serum, urine and bile from two patients with acute graft rejection
49. Effects of corticosteroids on cytokine generation and expression of activation antigens by monocytes in bronchial asthma
50. Effects of glucocorticoids in rheumatoid arthritis Diminished glucocorticoid receptors do not result in glucocorticoid resistance
51. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival
52. The inhibitor cytokine interleukin-1 receptor antagonist synergistically augments cyclosporine immunosuppression in a rat cardiac allograft model
53. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens
54. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra arthritis study group
55. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
56. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease